microRNA-125b promotes leukemia cell resistance to daunorubicin by inhibiting apoptosis

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1909-1916

  Zhou, Lili ^a   Bai, Haitao ^a   Wang, Chun ^a   Wei, Daolin ^a   Qin, Youwen ^a   Xu, Xiaowei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Acute leukemia; Daunorubicin; GRK2; microRNA 125b; PUMA

Indexed keywords

DAUNORUBICIN; G PROTEIN COUPLED RECEPTOR KINASE 2; MICRORNA 125B; PUMA PROTEIN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; JURKAT CELL LINE; LEUKEMIA CELL LINE; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUKEMIA; MALE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; YOUNG ADULT;

EID: 84899508546     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2011     Document Type: Article

References (37)

1. Kimby E, Nygren P and Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 40: 231-252, 2001.
2. Tallman MS, Gilliland DG and Rowe JM: Drug therapy for acute myeloid leukemia. Blood 106: 1154-1163, 2005.
3. Pulte D, Gondos A and Brenner H: Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Ann Oncol 21: 335-341, 2010.
4. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
5. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
6. Lim LP, Lau NC, Garrett-Engele P, et al: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773, 2005.
7. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
8. Kim JK, Noh JH, Jung KH, et al: Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 57: 1055-1067, 2013.
9. Zhou M, Liu Z, Zhao Y, et al: MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285: 21496-21507, 2010.
10. Yuxia M, Zhennan T and Wei Z: Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol 138: 2045-2050, 2012.
11. Kappelmann M, Kuphal S, Meister G, Vardimon L and Bosserhoff AK: MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene 32: 2984-2991, 2013.
12. Nishida N, Yokobori T, Mimori K, et al: MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol 38: 1437-1443, 2011.
13. Bousquet M, Quelen C, Rosati R, et al: Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 205: 2499-2506, 2008.
14. Enomoto Y, Kitaura J, Hatakeyama K, et al: Eμ/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 25: 1849-1856, 2011.
15. Klusmann JH, Li Z, Böhmer K, et al: miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 24: 478-490, 2010.
16. Gefen N, Binder V, Zaliova M, et al: Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia 24: 89-96, 2010.
17. Calin GA, Liu CG, Sevignani C, et al: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 101: 11755-11760, 2004.
18. Zhang H, Luo XQ, Feng DD, et al: Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 10: 108, 2011.
19. Schotte D, De Menezes RX, Akbari Moqadam F, et al: MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 96: 703-711, 2011.
20. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115: 453-474, 2010.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
22. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al: Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med 16: 49-58, 2010.
23. Hughes MS, Yu YY, Dudley ME, et al: Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 16: 457-472, 2005.
24. Stark A, Brennecke J, Russell RB and Cohen SM: Identification of Drosophila MicroRNA targets. PLoS Biol 1: 397-409, 2003.
25. Husted S, Søkilde R, Rask L, et al: MicroRNA expression profiles associated with development of drug resistance in Ehrlich ascites tumor cells. Mol Pharm 8: 2055-2062, 2011.
26. Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD and Kufe D: Mucin 1 oncoprotein expression is suppressed by the miR-125b oncomir. Genes Cancer 1: 62-68, 2010.
27. Iida K, Fukushi J, Matsumoto Y, et al: miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int 13: 21, 2013.
28. Kong F, Sun C, Wang Z, et al: miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 31: 543-549, 2011.
29. Richardson DS and Johnson SA: Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 11: 201-223, 1997.
30. Gong J, Zhang JP, Li B, et al: MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 32: 3071-3079, 2013.
31. Shi L, Zhang S, Feng K, et al: MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 40: 119-129, 2012.
32. Balakrishnan A, Stearns AT, Park PJ, et al: Upregulation of proapoptotic microRNA mir-125a after massive small bowel resection in rats. Ann Surg 255: 747-753, 2012.
33. Zeng CW, Zhang XJ, Lin KY, et al: Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways. Mol Pharmacol 81: 578-586, 2012.
34. Jiang F, Liu T, He Y, et al: MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 11: 425, 2011.
35. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D and Aguiar RC: MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 109: 7865-7870, 2012.
36. Tan G, Niu J, Shi Y, Ouyang H and Wu ZH: NF-κB-dependent microRNA-125b up-regulation promotes cell survival by targeting p38α upon ultraviolet radiation. J Biol Chem 287: 33036-33047, 2012.
37. Bousquet M, Nguyen D, Chen C, et al: MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA. Haematologica 97: 1713-1721, 2012.